Regeneron Reports First Quarter 2016 Financial and Operating Results

TARRYTOWN, N.Y.,May 5, 2016/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced financial results for the first quarter of 2016 and provided a business update.

($ in millions, except per share data)

EYLEA U.S. net product sales

$

781

$

541

44%

Total revenues

$

1,201

$

870

38%

Non-GAAP net income(2)

$

293

$

336

(13%)

Non-GAAP net income per share - diluted(2)

$

2.57

$

2.88

(11%)

GAAP net income

$

166

$

76

118%

GAAP net income per share - diluted

$

1.45

$

0.66

120%

"The year is off to a very productive start at Regeneron.  This quarter, we saw continued strong sales growth with EYLEA, made additional launch progress with Praluent, prepared for the potential launch of sarilumab, and reported important new data across our pipeline," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.  "Our innovative new therapy dupilumab showed positive results across two Phase 3 trials in moderate-to-severe atopic dermatitis, a debilitating disease with very limited treatment options, and we look forward to submitting a Biologics License Application to the U.S. FDA in the third quarter."

EYLEA®(aflibercept) Injection for Intravitreal Injection

• In the first quarter of 2016, net sales of EYLEA inthe United Statesincreased 44% to$781 millionfrom$541 millionin the first quarter of 2015. Overall distributor inventory levels remained within the Company's one- to two-week targeted range.

• Bayer commercializes EYLEA outsidethe United States. In the first quarter of 2016, net sales of EYLEA outside ofthe United States(1)were$419 million, compared to$292 millionin the first quarter of 2015. In the first quarter of 2016, Regeneron recognized$146 millionfrom its share of net profit from EYLEA sales outsidethe United States, compared to$89 millionin the first quarter of 2015.

• A Phase 3 study of EYLEA for the treatment of non-proliferative diabetic retinopathy in patients without diabetic macular edema (DME) was initiated in the first quarter of 2016.

Praluent®(alirocumab) Injection for the Treatment of High Low-Density Lipoprotein (LDL) Cholesterol

• In the first quarter of 2016, net sales of Praluent were$13 million. Product sales for Praluent are recorded by Sanofi, and the Company shares in any profits or losses from the commercialization of Praluent. Praluent was launched inthe United Statesin the third quarter of 2015 and in certain countries in the European Union commencing in the fourth quarter of 2015.

• InMarch 2016, the Company and Sanofi reported data from the Phase 3 ODYSSEY ESCAPE study in patients with heterozygous familial hypercholesterolemia (HeFH) who were undergoing LDL apheresis therapy. The trial achieved its primary endpoint, demonstrating that patients who added Praluent to their existing treatment regimen significantly reduced the frequency of their apheresis therapy by 75%, compared to placebo.

• In the first quarter of 2016, the Data Monitoring Committee (DMC) of the ODYSSEY OUTCOMES study for Praluent completed the first interim analysis. In accordance with the protocol, the DMC performed a futility assessment. The DMC recommended the study continue with no changes. Regeneron remains blinded to the actual results of this analysis. The ongoing ODYSSEY OUTCOMES trial is assessing the potential of Praluent to demonstrate cardiovascular benefit.

Regeneron has thirteen product candidates in clinical development.  These consist of EYLEA and twelve fully human monoclonal antibodies generated using the Company'sVelocImmune®technology, including four in collaboration with Sanofi.  In addition to EYLEA and Praluent, highlights from the antibody pipeline include:

Sarilumab, the Company's antibody targeting IL-6R for rheumatoid arthritis, is currently being studied in the global Phase 3 SARIL-RA program.

• InMarch 2016, the Company and Sanofi reported results from the 24-week Phase 3 SARIL-RA-MONARCH study in adult patients with active rheumatoid arthritis who were inadequate responders to, intolerant of, or inappropriate candidates for methotrexate (MTX) therapy. The study met its primary endpoint, demonstrating that sarilumab monotherapy was superior to adalimumab monotherapy (marketed by AbbVie Inc. as HUMIRA®).

• InDecember 2015, the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for sarilumab, with a target action date ofOctober 30, 2016.

Dupilumab, the Company's antibody that blocks signaling of IL-4 and IL-13, is currently being studied in atopic dermatitis, asthma, nasal polyps, and eosinophilic esophagitis.

• InApril 2016, the Company and Sanofi reported that the Phase 3 LIBERTY AD SOLO 1 and SOLO 2 trials evaluating dupilumab in adult patients with inadequately controlled moderate-to-severe atopic dermatitis met their primary endpoints.

• A Phase 2 study of dupilumab in pediatric patients (6-17 years of age) with moderate-to-severe atopic dermatitis is fully enrolled and ongoing.

• A Phase 3 pivotal study of dupilumab in patients with uncontrolled persistent asthma continues to enroll patients.

• A Phase 2 study of dupilumab in eosinophilic esophagitis is ongoing.

Fasinumab, the Company's antibody targeting Nerve Growth Factor (NGF), is currently being studied in patients with pain due to osteoarthritis and lower back pain.

• The Company recently reported results from a Phase 2/3 study evaluating fasinumab in patients with moderate-to-severe osteoarthritis pain of the hip or knee who have a history of inadequate pain relief or intolerance to current analgesic therapies. The study met its primary endpoint at 16 weeks.

• In the first quarter of 2016, the Company initiated a Phase 3 long-term safety and efficacy study of fasinumab in patients with pain due to osteoarthritis of the knee or hip, and this trial is currently enrolling patients.

• In the first quarter of 2016, the Company also initiated a Phase 2b/3 study of fasinumab in chronic lower back pain.

REGN2810, an antibody to programmed cell death protein 1 (PD-1), entered a potentially pivotal clinical study for the treatment of advanced cutaneous squamous cell carcinoma in the second quarter of 2016.

Nesvacumab/aflibercept, a combination product comprised of an antibody to angiopoietin-2 (Ang2) co-formulated with aflibercept for intravitreal injection for use in ophthalmology, entered Phase 2 clinical development for the treatment of neovascular age-related macular degeneration (wet AMD) and DME in the first quarter of 2016.

Evinacumab, an antibody to Angptl-3, was granted orphan-drug designation by the FDA in the first quarter of 2016.  Clinical studies are ongoing for the treatment of homozygous familial hypercholesterolemia and severe forms of hyperlipidemia.

REGN2176-3 (PDGFR-betaAntibody co-formulated withaflibercept)

•

Report results from Phase 2 study

Praluent

•

DMC interim analysis of ODYSSEY OUTCOMES trial

•

Ongoing launch in additional countries

Sarilumab (IL-6R Antibody)

•

FDA target action date of October 30, 2016

•

File for regulatory approvals outside the United States

Dupilumab (IL-4R Antibody)

•

Report primary endpoint results from Phase 3CHRONOS study in atopic dermatitis

•

Complete rolling BLA submission for atopic dermatitis inthe United States

•

Initiate Phase 3 study in pediatric patients in atopicdermatitis

REGN2810 (PD-1 Antibody)

•

Report data from Phase 1 study in patients with cancer

• In the first quarter of 2016, theNew England Journal of Medicinepublished a Regeneron Genetics Center paper showing that inactivating mutations of the angiopoeitin-like 4 (ANGPTL4) gene are associated with a significantly reduced risk of coronary artery disease in humans.  ANGPTL4 and ANGPTL3 are thought to be related inhibitors of lipoprotein lipase (LPL).

• InMarch 2016, the Company and Bayer entered into a collaboration agreement to jointly develop a combination therapy of the Ang2 antibody nesvacumab and aflibercept for the treatment of serious eye diseases.

• InApril 2016, the Company and Intellia Therapeutics, Inc. entered into a license and collaboration agreement to advance CRISPR/Cas gene-editing technology forin vivotherapeutic development. In addition to the discovery, development and commercialization of new therapies, the companies will focus on technology development of the CRISPR/Cas platform.

Product Revenues:Net product sales were$784 millionin the first quarter of 2016, compared to$545 millionin the first quarter of 2015.  EYLEA net product sales inthe United Stateswere$781 millionin the first quarter of 2016, compared to$541 millionin the first quarter of 2015.

Total Revenues:Total revenues, which include product revenues described above, increased by 38% to$1.201 billionin the first quarter of 2016, compared to$870 millionin the first quarter of 2015.  Total revenues also include collaboration revenues of$399 millionin the first quarter of 2016, compared to$297 millionin the first quarter of 2015.  Collaboration revenues in the first quarter of 2016 increased primarily due to higher reimbursement of the Company's research and development expenses under its antibody collaboration with Sanofi, an increase in the Company's net profit from commercialization of EYLEA outsidethe United States, and reimbursement of the Company's research and development expenses and amortization of up-front payments received in connection with the Company'sJuly 2015immuno-oncology collaboration with Sanofi.

Refer to Table 4 for a summary of collaboration revenue.

Research and Development (R&D) Expenses:GAAP R&D expenses were$470 millionin the first quarter of 2016, compared to$343 millionin the first quarter of 2015.  The higher R&D expenses in the first quarter of 2016 were principally due to higher development costs primarily related to dupilumab and fasinumab, and higher headcount to support the Company's increased R&D activities, partly offset by lower development costs primarily related to Praluent.  In addition, in the first quarter of 2016, R&D-related non-cash share-based compensation expense was$78 million, compared to$60 millionin the first quarter of 2015.

Selling, General, and Administrative (SG&A) Expenses:GAAP SG&A expenses were$290 millionin the first quarter of 2016, compared to$159 millionin the first quarter of 2015.  The increase was primarily due to higher headcount, and higher commercialization expenses related to EYLEA and Praluent.  In addition, in the first quarter of 2016, SG&A-related non-cash share-based compensation expense was$60 million, compared to$42 millionin the first quarter of 2015.

Cost of Goods Sold (COGS):GAAP COGS was$79 millionin the first quarter of 2016, compared to$43 millionin the first quarter of 2015.  COGS primarily consists of royalties as well as costs in connection with producing U.S. EYLEA commercial supplies, and various start-up costs in connection with the Company's Limerick,Irelandcommercial manufacturing facility.  COGS increased principally due to the increase in U.S. EYLEA net product sales, as well as an increase in Limerick start-up costs.

Income Tax Expense:In the first quarter of 2016, GAAP income tax expense was$164 millionand the effective tax rate was 49.8%, compared to$201 millionand 72.5% in the first quarter of 2015.  The effective tax rate for the first quarter of 2016 was negatively impacted, compared to the U.S. federal statutory rate, by losses incurred in foreign jurisdictions with rates lower than the federal statutory rate and the non-tax deductible Branded Prescription Drug Fee, partly offset by the federal tax credit for increased research activities and the domestic manufacturing deduction.  The effective tax rate for the first quarter of 2015 was negatively impacted primarily by losses incurred in foreign jurisdictions with rates lower than the federal statutory rate, the non-tax deductible Branded Prescription Drug Fee, and expiration, at the end of 2014, of the federal tax credit for increased research activities.

The non-GAAP income tax adjustment in the first quarter of 2016 is primarily related to the cash taxes the Company expects to be paid or payable in 2016 in connection with the immuno-oncology up-front payment that the Company received in 2015, partly offset by the excess tax benefit associated with stock option exercises.  The non-GAAP income tax adjustment in the first quarter of 2015 was primarily related to the Company's tax credit carry-forwards available for tax purposes and excess tax benefits in connection with stock option exercises.

Non-GAAP and GAAP Net Income:The Company reported non-GAAP net income of$293 million, or$2.81per basic share and$2.57per diluted share, in the first quarter of 2016, compared to non-GAAP net income of$336 million, or$3.28per basic share and$2.88per diluted share, in the first quarter of 2015.

The Company reported GAAP net income of$166 million, or$1.59per basic share and$1.45per diluted share, in the first quarter of 2016, compared to GAAP net income of$76 million, or$0.74per basic share and$0.66per diluted share, in the first quarter of 2015.

A reconciliation of the Company's GAAP to non-GAAP results is included in Table 3 of this press release.

The Company's updated full year 2016 financial guidance consists of the following components:

EYLEA U.S. net product sales

20% - 25% growth over 2015(previously approximately 20% growth over 2015)

Sanofi reimbursement of Regeneroncommercialization-related expenses

$320 million - $370 million

Non-GAAP unreimbursed R&D(2)

$875 million - $950 million(reaffirmed)

Non-GAAP SG&A(2)

$925 million - $1.0 billion(reaffirmed)

Cash tax as a % of non-GAAP pre-tax income(2)

35% - 45%*(reaffirmed)

Capital expenditures

$550 million - $625 million(previously $580 million - $680 million)

* - Includes a non-recurring tax payment of approximately $222 million related to the immuno-oncology upfront payment from Sanofi that the Company received in 2015.

(1)

Regeneron records net product sales of EYLEA in the United States.  Outside the United States, EYLEA net product sales comprise sales by Bayer in countries other than Japan and sales by Santen Pharmaceutical Co., Ltd. in Japan under a co-promotion agreement with an affiliate of Bayer.  The Company recognizes its share of the profits (including a percentage on sales in Japan) from EYLEA sales outside the United States within "Bayer collaboration revenue" in its Statements of Operations.

(2)

This press release uses non-GAAP net income, non-GAAP net income per share, non-GAAP unreimbursed R&D, non-GAAP SG&A, and cash tax as a percentage of non-GAAP pre-tax income, which are financial measures that are not calculated in accordance with U.S. Generally Accepted Accounting Principles ("GAAP").  The Company believes that the presentation of these non-GAAP measures is useful to investors because they exclude, as applicable: (i) non-cash share-based compensation expense, which fluctuates from period to period based on factors that are not within the Company's control, such as the Company's stock price on the dates share-based grants are issued; (ii) non-cash interest expense related to the Company's convertible senior notes, since this is not deemed useful in evaluating the Company's operating performance; and (iii) loss on extinguishment of debt, since this non-cash charge is based on factors that are not within the Company's control.  Non-GAAP measures also include income tax expense adjustments to consider the tax effect of reconciling items and an adjustment from GAAP tax expense to the amount of taxes that are paid or payable in cash in respect of the current period.  As there has been a significant difference between the Company's effective tax rate and actual cash income taxes paid or payable, GAAP income tax expense is not deemed useful in evaluating the Company's operating performance.  Non-GAAP unreimbursed R&D represents non-GAAP R&D expenses reduced by R&D expense reimbursements from the Company's collaboration partners.  Management uses these non-GAAP measures for planning, budgeting, forecasting, assessing historical performance, and making financial and operational decisions, and also provides forecasts to investors on this basis.  However, there are limitations in the use of these and other non-GAAP financial measures as they exclude certain expenses that are recurring in nature.  Furthermore, the Company's non-GAAP financial measures may not be comparable with non-GAAP information provided by other companies.  Any non-GAAP financial measure presented by Regeneron should be considered supplemental to, and not a substitute for, measures of financial performance prepared in accordance with GAAP.  A reconciliation of the Company's historical GAAP to non-GAAP results is included in Table 3 of this press release.

(3)

The Company's 2016 financial guidance does not assume the completion of any significant business development transactions not completed as of the date of this press release.

Regeneron will host a conference call and simultaneous webcast to discuss its first quarter 2016 financial and operating results onThursday, May 5, 2016, at8:30 AM.  To access this call, dial (888) 771-4371 (U.S.) or (847) 585-4405 (International).  A link to the webcast may be accessed from the "Events and Presentations" page of Regeneron's website atwww.regeneron.com.  A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days.

Regeneron is a leading science-based biopharmaceutical company based inTarrytown, New Yorkthat discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron commercializes medicines for high LDL cholesterol, eye diseases, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, atopic dermatitis, pain, and infectious diseases.  For additional information about the Company, please visitwww.regeneron.comor follow @Regeneron on Twitter.

This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may differ materially from these forward-looking statements.  Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words.  These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's products, product candidates, and research and clinical programs now underway or planned; the likelihood and timing of achieving any of the anticipated milestones described in this news release; unforeseen safety issues resulting from the administration of products and product candidates in patients, including serious complications or side effects in connection with the use of Regeneron's product candidates in clinical trials; the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates and new indications for marketed products, including without limitation EYLEA®(aflibercept) Injection and Praluent®(alirocumab) Injection, sarilumab, dupilumab, fasinumab, REGN2810, nesvacumab/aflibercept, and evinacumab; ongoing regulatory obligations and oversight impacting Regeneron's marketed products (such as EYLEA and Praluent), research and clinical programs, and business, including those relating to patient privacy; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's products and product candidates; competing drugs and product candidates that may be superior to Regeneron's products and product candidates; uncertainty of market acceptance and commercial success of Regeneron's products and product candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), on the commercial success of Regeneron's products and product candidates; the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates; coverage and reimbursement determinations by third-party payers, including Medicare and Medicaid; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its sales or other financial projections or guidance and changes to the assumptions underlying those projections or guidance, including without limitation those relating to EYLEA U.S. net product sales, Sanofi reimbursement of Regeneron commercialization-related expenses, non-GAAP unreimbursed R&D, non-GAAP SG&A, cash tax as a percentage of non-GAAP pre-tax income, and capital expenditures; the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi and Bayer HealthCare LLC (or their respective affiliated companies, as applicable), to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating thereto.  A more complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the fiscal year endedDecember 31, 2015and its Form 10-Q for the quarterly period endedMarch 31, 2016.  Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron.  Regeneron does not undertake any obligation to update publicly any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com/regeneron).

This press release and/or the financial results attached to this press release include amounts that are considered "non-GAAP financial measures" under SEC rules.  As required, Regeneron has provided reconciliations of historical non-GAAP financial measures.

TABLE 1

Assets:

Cash and marketable securities

$

1,404,389

$

1,677,385

Accounts receivable - trade, net

1,450,572

1,152,489

Accounts receivable from Sanofi and Bayer

414,649

315,304

Inventories

303,294

238,578

Deferred tax assets

543,689

461,945

Property, plant, and equipment, net

1,666,391

1,594,120

Other assets

121,476

169,311

Total assets

$

5,904,460

$

5,609,132

Liabilities and stockholders' equity:

Accounts payable, accrued expenses, and other liabilities

$

855,412

$

760,619

Deferred revenue

909,371

818,166

Facility lease obligations

364,136

364,708

Convertible senior notes

10,459

10,802

Stockholders' equity

3,765,082

3,654,837

Total liabilities and stockholders' equity

$

5,904,460

$

5,609,132

TABLE 2

Revenues:

Net product sales

$

784,182

$

544,573

Sanofi collaboration revenue

219,694

173,356

Bayer collaboration revenue

179,592

123,846

Other revenue

17,381

27,837

1,200,849

869,612

Expenses:

Research and development

470,112

343,113

Selling, general, and administrative

289,677

158,991

Cost of goods sold

78,942

42,570

Cost of collaboration and contract manufacturing

32,810

41,385

871,541

586,059

Income from operations

329,308

283,553

Other income (expense), net

843

(7,030)

Income before income taxes

330,151

276,523

Income tax expense

(164,415)

(200,502)

Net income

$

165,736

$

76,021

Net income per share - basic

$

1.59

$

0.74

Net income per share - diluted

$

1.45

$

0.66

Weighted average shares outstanding - basic

104,290

102,227

Weighted average shares outstanding - diluted

114,228

114,519

TABLE 3

GAAP net income

$

165,736

$

76,021

Adjustments:

R&D: Non-cash share-based compensation expense

78,102

59,502

SG&A: Non-cash share-based compensation expense

60,082

42,175

COGS and COCM: Non-cash share-based compensation expense

4,066

2,082

Other expense: Non-cash interest and loss on extinguishment related to convertiblesenior notes

84

3,190

Non-cash income taxes

(15,271)

152,568

Non-GAAP net income

$

292,799

$

335,538

Non-GAAP net income per share - basic

$

2.81

$

3.28

Non-GAAP net income per share - diluted(a)

$

2.57

$

2.88

Shares used in calculating:

Non-GAAP net income per share - basic

104,290

102,227

Non-GAAP net income per share - diluted(b)

113,859

116,506

(a)

For diluted non-GAAP net income per share calculations, interest expense related to the contractual coupon interest rate on the Company's 1.875% convertible senior notes were excluded since these securities were dilutive.  Such interest expense was not material for the three months ended March 31, 2016 and 2015.

(b)

Weighted average shares outstanding includes the dilutive effect, if any, of employee stock options, restricted stock awards, convertible senior notes, and warrants.

TABLE 4

Sanofi collaboration revenue:

Reimbursement of Regeneron research and development expenses

$

222,877

$

169,506

Reimbursement of Regeneron commercialization-related expenses

73,274

8,458

Regeneron's share of losses in connection with commercialization of antibodies

(99,422)

(22,405)

Other

22,965

17,797

Total Sanofi collaboration revenue

219,694

173,356

Bayer collaboration revenue:

Regeneron's net profit in connection with commercialization of EYLEA outside theUnited States

145,835

89,426

Sales milestones

—

15,000

Cost-sharing of Regeneron development expenses

4,639

3,911

Other

29,118

15,509

Total Bayer collaboration revenue

179,592

123,846

Total collaboration revenue

$

399,286

$

297,202